Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.36 |
| ▸ | FDPS | P14324 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064783 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1SMPD1FDPS | |
| Ether SCHEMBL3217002 | 0.93 | TSHR (0.35) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL5965448 | 0.89 | DNM1 (0.46) | TSHRTHRBSMPD1FDPSMEN1 | |
| SCHEMBL14902960 | 0.83 | THRB (0.38) | TSHRTHRBGGPS1MEN1MAPT | |
| SCHEMBL28255184 | 0.81 | SMPD1 (0.42) | GGPS1SMPD1FDPSMEN1MAPT | |
| SCHEMBL13620249 | 0.81 | SMPD1 (0.42) | GGPS1SMPD1FDPSMEN1MAPT | |
| SCHEMBL27891743 | 0.81 | SMPD1 (0.42) | GGPS1SMPD1FDPSMEN1MAPT | |
| SCHEMBL7806975 | 0.80 | TDP1 (0.47) | TSHRMEN1KMT2A | |
| SCHEMBL10885977 | 0.80 | MEN1 (0.41) | GGPS1SMPD1FDPSMEN1MAPT | |
| SCHEMBL22903085 | 0.80 | TSHR (0.40) | TSHRTHRBGGPS1SMPD1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828151-B1 | MALONAMIDE DERIVATIVES AS INHIBITORS OF GAMMA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-1828151-A2 | MALONAMIDE DERIVATIVES AS INHIBITORS OF GAMMA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-7211573-B2 | Malonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| WO-2006061136-A2 | MALONAMIDE DERIVATIVES AS INHIBITORS OF GAMMA-SECRETASE FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122168-A1 | Malonamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122168-A1 | Malonamide derivatives | ACE, REN, ME1 | TSHR 1637/4885THRB 2448/4885GGPS1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.